SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-306352
Filing Date
2022-12-16
Accepted
2022-12-16 06:07:11
Documents
14
Period of Report
2022-12-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d381959d8k.htm   iXBRL 8-K 33218
2 EX-4.1 d381959dex41.htm EX-4.1 69481
3 EX-10.1 d381959dex101.htm EX-10.1 248837
  Complete submission text file 0001193125-22-306352.txt   565448

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA evlo-20221215.xsd EX-101.SCH 2843
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE evlo-20221215_lab.xml EX-101.LAB 17980
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE evlo-20221215_pre.xml EX-101.PRE 11254
8 EXTRACTED XBRL INSTANCE DOCUMENT d381959d8k_htm.xml XML 3345
Mailing Address 620 MEMORIAL DRIVE SUITE 500 CAMBRIDGE MA 02139
Business Address 620 MEMORIAL DRIVE SUITE 500 CAMBRIDGE MA 02139 617-577-0300
Evelo Biosciences, Inc. (Filer) CIK: 0001694665 (see all company filings)

IRS No.: 465594527 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38473 | Film No.: 221466371
SIC: 2834 Pharmaceutical Preparations